Perspectives on risk and regulation
Subtitle: the FDA at 100
By: editors, Arthur Daemmrich and Joanna Radin.
Contributors: Daemmrich, Arthur A.; Radin, Joanna.; Chemical Heritage Foundation.
Publisher: Chemical Heritage Foundation
Published: 2007
Place of publication: Philadelphia, Pa
Language: eng
ISBN-13: 9780941901420
Subjects: United States. -- Food and Drug Administration; United States. -- Food and Drug Administration; Food law and legislation -- United States; Drugs -- Law and legislation -- United States; Medical instruments and apparatus -- Law and legislation -- United States; Dietary supplements -- Law and legislation -- United States; Legislation, Drug -- United States; Legislation, Food -- United States; Dietary Supplements -- standards -- United States; Equipment and Supplies -- standards -- United States; Government Agencies -- United States
Notes: Includes bibliographical references.
Table of contents: title: Introduction: historical and contemporary perspectives on the FDA / Arthur Daemmrich and Joanna Radin; title: Turning points in FDA history / Peter Barton Hutt; title: FDA initiatives to improve safety: perspectives on drug benefits and risks / Steven Galson; title: Envisioning the future of pharmaceutical regulation / Ronald Krall; title: Regulating medical devices / Daniel Schultz; title: From hand drawings to hard data: reflections on thirty years of medical device regulation / Robert O'Holla; title: First discussion session: drug and medical device regulation; title: Regulation at home and abroad: securing food safety in a global and local consumer market / Robert Brackett; title: Taking a closer look at the label: an industry perspective on FDA guidance / Idamarie Laquatra; title: Science and public health in the FDA's regulation of dietary supplements / Barbara Schneeman; title: Regulation at a crossroads: the FDA and the future of the dietary supplement industry / Steven Mister; title: Second discussion session: food and dietary supplement regulation; title: Navigating the molecular revolution: FDA leadership in a time of transition / Andrew C. von Eschenbach.